fimasartan
Trade name: kanarb
Small moleculeexperimental
Fimasartan is a non-peptide angiotensin II receptor antagonist (ARB) used for the treatment of hypertension and heart failure. Through oral administration, fimasartan blocks angiotensin II receptor type 1 (AT1 receptors), reducing pro-hypertensive actions of angiotensin II, such as systemic vasoconstriction and water retention by the kidneys. Concurrent administration of fimasartan with diuretic hydrochlorothiazide has shown to be safe in clinical trials. Fimasartan was approved for use in South Korea on September 9, 2010, and is available under the brand name Kanarb through Boryung Pharmaceuticals, who are presently seeking worldwide partnership. — Wikipedia
Clinical trial activity
64 trials · 48 clinical orgs · 0 marketing orgs
Phase 1
32
Phase 2
21
Phase 3
15
Phase 4
10
Earliest trial started Sep 1, 2003 (NCT01289886)
Timeline
Indications
Approved for
Studied for
- Aortic Stenosis, Subvalvular · Phase 4
- Atherosclerosis · Phase 4
- Blood Pressure · Phase 4
- Coronary Artery Disease · Phase 4
- Coronary Disease · Phase 4
- Diabetes Mellitus · Phase 1
- Diabetes Mellitus, Type 2 · Phase 4
- Drug Interactions · Phase 1
- Dyslipidemias · Phase 3
- Essential Hypertension · Phase 4
- Healthy Volunteers · Phase 1
- Hypercholesterolemia · Phase 3
- Hyperlipidemias · Phase 1
- Hypertension · Phase 4
- Intermittent Claudication · Phase 1
- Ischemic Stroke · Phase 4
- Kidney Failure, Chronic · Phase 1
- Liver Diseases · Phase 1
- Pharmacokinetics · Phase 1
- Renal Insufficiency, Chronic · Phase 3
- Renin-Angiotensin System · Phase 4
Mechanism of action
- Angiotensin II receptorANTAGONIST
Angiotensin II receptor antagonist
- Type-1 angiotensin II receptorANTAGONIST
Type-1 angiotensin II receptor antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1- Mol. weight
- 501.66 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1951143 ↗
- WikipediaFimasartan ↗
- ChEMBLCHEMBL4297548 ↗
- ChEMBLCHEMBL1951146 ↗
Also known as
- br-a657
- br-a-657
- br-a-657
- br-a-657
- fimasartan
- fimasartan
- fimasartan
- fimasartan
- fimasartan
- fimasartan
- fimasartan
- fimasartan
- fimasartan
- fimasartan potassium
- fimasartan potassium hydrate
- fimasartan potassium trihydrate
- fimsartan
- kanarb
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06167265 | Phase 1 | Nov 28, 2023 | Cliantha Research Limited, Genovate Biotechnology Co., Ltd., |
| NCT05930028 | Phase 3 | Jul 13, 2023 | Boryung Pharmaceutical Company |
| NCT05699070 | Phase 1 | Feb 15, 2023 | Daewoong Pharmaceutical Co. LTD. |
| NCT05878561 | Phase 3 | Nov 9, 2022 | Boryung Pharmaceutical Company |
| NCT05466734 | Phase 1 | Jul 30, 2022 | Bio-Kinetic Clinical Applications, Genovate Biotechnology Co., Ltd., |
| NCT05191862 | Phase 1 | Apr 23, 2022 | Genovate Biotechnology Co., Ltd., |
| NCT03991442 | Phase 3 | Jun 17, 2019 | Boryung Pharmaceutical Company |
| NCT03629067 | Phase 1 | Aug 31, 2018 | Boryung Pharmaceutical Company, Seoul National University |
| NCT03609294 | Phase 1 | Jul 18, 2018 | Boryung Pharmaceutical Company, Seoul National University |
| NCT03338426 | Phase 3 | Jan 15, 2018 | Boryung Pharmaceutical Company |
| NCT05173025 | Phase 4 | Jan 1, 2018 | Seoul National University |
| NCT03390465 | Phase 1 | Dec 15, 2017 | Boryung Pharmaceutical Company, Inje University |
| NCT03294070 | Phase 4 | Sep 30, 2017 | Government of Mexico |
| NCT03250052 | Phase 1 | Aug 14, 2017 | Boryung Pharmaceutical Company, Kyungpook University |
| NCT03246555 | Phase 3 | Aug 7, 2017 | Boryung Pharmaceutical Company |
| NCT03156842 | Phase 3 | May 31, 2017 | Boryung Pharmaceutical Company |
| NCT02994745 | Phase 1 | Dec 23, 2016 | Boryung Pharmaceutical Company |
| NCT02920047 | Phase 1 | Oct 1, 2016 | Boryung Pharmaceutical Company, Seoul National University |
| NCT02995720 | Phase 1 | Aug 26, 2016 | Boryung Pharmaceutical Company |
| NCT02704702 | Phase 1 | Mar 1, 2016 | Boryung Pharmaceutical Company, Celerion |
Showing 20 of 64 trials
Page 1 / 4
Organizations
Research & Development (48)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boryung Pharmaceutical Company | For profit | 55 | 49 | 4 | 2003 |
| Seoul National University | Academic/Hospital | 20 | 4 | 5 | 2007 |
| University of Ulsan | Academic/Hospital | 11 | 2 | 3 | 2007 |
| Kyungpook University | Academic/Hospital | 10 | 0 | 3 | 2008 |
| Catholic University of Korea | Academic/Hospital | 9 | 0 | 4 | 2007 |
| Yonsei University | Academic/Hospital | 8 | 0 | 4 | 2007 |
| Inje University | Academic/Hospital | 7 | 0 | 3 | 2008 |
| Korea University | Academic/Hospital | 7 | 0 | 3 | 2008 |
| Chonnam National University | Academic/Hospital | 6 | 0 | 3 | 2008 |
| Hanyang University | Academic/Hospital | 5 | 0 | 2 | 2008 |
| Sungkyunkwan University | Academic/Hospital | 5 | 0 | 3 | 2007 |
| Daegu Catholic University | Academic/Hospital | 4 | 0 | 2 | 2008 |
| Dongguk University | Academic/Hospital | 4 | 0 | 2 | 2008 |
| Kangbuk Samsung Hospital | Academic/Hospital | 4 | 0 | 2 | 2008 |
| Ajou University | Academic/Hospital | 3 | 1 | 2 | 2008 |
| Chungnam National University | Academic/Hospital | 3 | 0 | 2 | 2008 |
| Covance | For profit | 3 | 0 | 2 | 2003 |
| Genovate Biotechnology Co., Ltd., | For profit | 3 | 3 | 1 | 2022 |
| Hallym University | Academic/Hospital | 3 | 1 | 3 | 2011 |
| Jeju National University | Academic/Hospital | 3 | 0 | 2 | 2011 |
48 organizations
Page 1 / 3